Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease

Dementia and Geriatric Cognitive Disorders

Volumn 33, Issue 1, 2012, Pages 1-5

  Ringman, John M ^a   Coppola, Giovanni ^b   Elashoff, David ^a   Rodriguez Agudelo, Yaneth ^b   Medina, Luis D ^a   Gylys, Karen ^a   Cummings, Jeffrey L ^a   Cole, Greg M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

Amyloid, 42 amino acid form; APP gene; Biomarkers; Cerebrospinal fluid; Familial Alzheimer's disease, presymptomatic; PSEN1 gene; tau protein

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; PHOSPHORYLATED TAU PROTEIN; TAU PROTEIN; TOTAL TAU PROTEIN; UNCLASSIFIED DRUG;

AGE; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CORRELATIONAL STUDY; DEMENTIA; FAMILIAL DISEASE; GENE MUTATION; GENOTYPE; HUMAN; ONSET AGE; PRIORITY JOURNAL;

AGE FACTORS; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; COHORT STUDIES; DNA; EARLY DIAGNOSIS; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; PRESENILIN-1; TAU PROTEINS;

EID: 84856919991     PISSN: 14208008     EISSN: 14219824     Source Type: Journal    
DOI: 10.1159/000335729     Document Type: Article

References (27)

1. Thies W, Bleiler L: Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208-244.
2. Motter R, Vigo-Pelfrey C, Kholodenko D, et al: Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38:643-648.
3. Andreasen N, Vanmechelen E, Van de Voorde A, et al: Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community-based follow-up study. J Neurol Neurosurg Psychiatry 1998;64:298-305. (Pubitemid 28159831)
4. Zetterberg H, Hietala MA, Jonsson M, et al: Neurochemical aftermath of amateur boxing. Arch Neurol 2006;63:1277-1280. (Pubitemid 44379829)
5. Hesse C, Rosengren L, Andreasen N, et al: Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187-190. (Pubitemid 32011305)
6. Okonkwo OC, Mielke MM, Griffith HR, et al: Cerebrospinal fluid profiles and prospective course and outcome in patients with amnestic mild cognitive impairment. Arch Neurol 2011;68:113-119.
7. Mattsson N, Zetterberg H, Hansson O, et al: CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302:385-393.
8. Ringman JM: What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review. J Geriatr Psychiatry Neurol 2005;18:228-233.
9. Moonis M, Swearer JM, Dayaw MP, et al: Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology 2005;65:323-325. (Pubitemid 41022387)
10. Ringman JM, Younkin SG, Pratico D, et al: Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85-92.
11. Fortea J, Llado A, Bosch B, et al: Cerebrospinal fluid biomarkers in Alzheimer's disease families with PSEN1 mutations. Neurodegener Dis 2011;8:202-207.
12. Ringman JM, Taylor K, Teng E, Coppola G, Gylys K: Longitudinal change in CSF biomarkers in a presymptomatic carrier of an APP mutation. Neurology 2011;76:2124-2125.
13. Fox NC, Kennedy AM, Harvey RJ, et al: Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. Brain 1997;120:491-501.
14. Murrell J, Ghetti B, Cochran E, et al: The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 2006;7:277-279.
15. Mullan M, Tsuji S, Miki T, et al: Clinical comparison of Alzheimer's disease in pedigrees with the codon 717 Val→Ile mutation in the amyloid precursor protein gene. Neurobiol Aging 1993;14:407-419.
16. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
17. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997;9(suppl 1):173-176, discussion 177-178.
18. Apostolova LG, Hwang KS, Medina LD, et al: Cortical and hippocampal atrophy in patients with autosomal dominant familial Alzheimer's disease. Dement Geriatr Cogn Disord 2011;32:118-125.
19. Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E: Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. Arch Neurol 2010;67:217-223.
20. Lo RY, Hubbard AE, Shaw LM, et al: Longitudinal Change of Biomarkers in Cognitive Decline. Arch Neurol 2011;68:1257-1266.
21. Morris JC, Roe CM, Xiong C, et al: APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 2010;67:122-131.
22. Takao M, Ghetti B, Murrell JR, et al: Ectopic white matter neurons, a developmental abnormality that may be caused by the PSEN1 S169L mutation in a case of familial AD with myoclonus and seizures. J Neuropathol Exp Neurol 2001;60:1137-1152.
23. Ringman JM, Romano JD, Medina LD, et al: Increased prevalence of significant recurrent headache in preclinical familial Alzheimer's disease mutation carriers. Dement Geriatr Cogn Disord 2008;25:380-384. (Pubitemid 351562961)
24. Klunk WE, Price JC, Mathis CA, et al: Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-6184. (Pubitemid 46890033)
25. O'Riordan S, McMonagle P, Janssen JC, et al: Presenilin-1 mutation (E280G), spastic paraparesis, and cranial MRI white-matter abnormalities. Neurology 2002;59:1108-1110.
26. Scheuner D, Eckman C, Jensen M, et al: Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 1996;2:864-870. (Pubitemid 26296755)
27. Bateman RJ, Aisen PS, De Strooper B, et al: Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;2:35.